Compare Cytokinetics Inc (CYTK) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Northrop Grumman Corporation — how do they compare? Cytokinetics Inc trades at $75.96 (market cap $10.63B), while Northrop Grumman Corporation trades at $577.94 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 7.7× Cytokinetics Inc's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | NOC | |
|---|---|---|
Market Cap | $10.63B | $81.78B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $768.02 |
52-Week Low | $34.31 | $496.02 |
Enterprise Value | $10.74B | $95.77B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
Northrop Grumman (NOC) trades at $577.12, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $7.68, and raised full-year guidance, supported by a record $105 billion backlog. Revenue growth is steady, with 2026 projected at $42.9 billion, and profitability remains solid with a net income margin of 10.48%.
The outlook is positive, driven by strategic contracts like the $7.6 billion Sentinel program and defense spending tailwinds. Risks include margin pressures from specific programs and geopolitical uncertainties. Analysts are bullish with a consensus price target of $598.57, suggesting upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
